Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium‐90‐labeled murine HMFG1 without improvement in overall survival
- 10 April 2007
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 120 (12), 2710-2714
- https://doi.org/10.1002/ijc.22663
Abstract
This study analyzes the site of disease recurrence in ovarian cancer patients to assess the influence of a single intraperitoneal (IP) administration of yttrium‐90‐labeled murine monoclonal antibody HMFG1 (90Y‐muHMFG1) on the pattern of disease recurrence. In a large phase III trial ovarian cancer patients in complete clinical remission with FIGO stage Ic‐IV were randomized between standard treatment plus a single IP 90Y‐labeled muHMFG1 versus standard treatment alone after negative second‐look laparoscopy. Case report forms of all patients with disease recurrence were reviewed to determine site and date of recurrent disease. In total 447 patients were included in the study with a median follow‐up of 3.5 years. Relapse was seen in 104/224 in the active and 98/223 in the control arm. Significantly fewer IP (p < 0.05) and more extraperitoneal (p < 0.05) relapses occurred in the active treatment arm. Time to IP recurrence was significantly longer (p = 0.0019) and time to extraperitoneal recurrence was significantly shorter for the active treatment arm (p < 0.001). The impact of IP radioimmunotherapy on IP relapse‐free survival could only be seen in the subgroup of patients with residual disease after primary surgery (HR, 0.31; 95% CI, 0.18 to 0.53; p = 0.002). Although, there is no survival benefit for IP radioimmunotherapy as consolidation treatment for epithelial ovarian cancer, we found an improved control of IP disease, that was offset by increased extraperitoneal recurrences.Keywords
This publication has 15 references indexed in Scilit:
- Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete RemissionJournal of Clinical Oncology, 2006
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: A review of the literatureCritical Reviews in Oncology/Hematology, 2005
- Treatment goals in ovarian cancerInternational Journal of Gynecologic Cancer, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Intraperitoneal Radioactive Phosphorus (32P) Versus Observation After Negative Second-Look Laparotomy for Stage III Ovarian Carcinoma: A Randomized Trial of the Gynecologic Oncology GroupJournal of Clinical Oncology, 2003
- Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findingsObstetrics & Gynecology, 1999
- Analysis of Failures after Negative Second-Look in Patients with Advanced Ovarian Cancer: An Italian Multicenter StudyGynecologic Oncology, 1998
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapyGynecologic Oncology, 1991